Imaging for early stage breast cancer

A phase I/II trial in an Asian population

Dose escalation study 19 > 21 Gy Mobile Linac (Mobetron) 30 patients completed the protocol 50% suitable for ASTRO No Local Recurrence at 6 years No Regional or Distant Recurrence No breast cancer related deaths

A hypertrophic scar disappeared by the 3-year follow-up

A hypertrophic scar or keloid lasting for more than 3 years

Kawamura M et al, Radiat Oncol 2015